Publication – CD16 and Siglec expression refine the phenotypic heterogeneity of steady-state myeloid-derived suppressor cells.

St. Laurent Chris D. , Jame-Chenarboo Zeinab , Beck Alyssa E. , Stubblefield Stacey , Duan Shiteng , Sigal Darren , Macauley Matthew S.
CD16 and Siglec expression refine the phenotypic heterogeneity of steady-state myeloid-derived suppressor cells.
Frontiers in Oncology Volume 15 – 2025 DOI=10.3389/fonc.2025.1570121 2025 Jun

Read the article here.

ABSTRACT

Background: Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) mediate cancer immune suppression by promoting an immunosuppressive microenvironment that inhibits effective anti-tumor immunity. However, they are still a poorly understood, heterogeneous mix of neutrophil subsets. This study aims to determine the Siglec expression profile on several neutrophil subsets and assess their immunosuppressive ability.

Methods: We identified CD16high and CD16low neutrophil subsets from the low-density fractions of human peripheral blood and compared them to high-density neutrophils. We profiled the expression of the entire family of Siglecs on these three key neutrophil populations under steady-state conditions in healthy subjects as well as cancer patients. Moreover, the ability of these populations, isolated from healthy subjects, to suppress T cell proliferation was assessed.

Results: Two distinct subpopulations were investigated within the low-density fraction of human peripheral blood (CD15+CD66b+CD16low and CD15+CD66b+CD16high) and compared to high-density neutrophils (CD15+CD66b+CD16high). We found that in addition to CD33 (Siglec-3), Siglec-5/-14, -7, and -9, are differentially expressed on the CD16low and CD16high low-density subsets in both healthy, steady-state subjects, and cancer patients. Upregulated expression of CD33 on the CD16low cells led to the initial speculation that they are MDSCs. As the differential expression of Siglec-9 between these two populations was striking, we used CD16 and Siglec-9 double staining to quantify these populations, which demonstrated that the CD16lowSiglec-9low population is greatly upregulated in cancer patients. The CD16high low-density and high-density neutrophils, but not the CD16low low-density neutrophils from healthy subjects, inhibited T cell proliferation, indicating that the CD16lowSiglec-9low population are not MDSCs.

Conclusions: These results demonstrate that Siglecs are differentially expressed on neutrophil subsets, and along with CD16, may be used to help further define what is a PMN-MDSC. Consistent with current observations by others, PMN-MDSCs may encompass an array of neutrophil subtypes, including low-density neutrophils, and point to the need for more work to precisely define the genetic signatures of PMN-MDSCs.

Territorial Acknowledgement

The University of Alberta, its buildings, labs, and research stations are primarily located on the traditional territory of Cree, Blackfoot, Métis, Nakota Sioux, Iroquois, Dene, and Ojibway/Saulteaux/Anishinaabe nations; lands that are now known as part of Treaties 6, 7, and 8 and homeland of the Métis. The University of Alberta respects the sovereignty, lands, histories, languages, knowledge systems, and cultures of First Nations, Métis and Inuit nations.

Scroll to Top